Ten years and roughly $2 billion. That's the widely cited cost and timeline for bringing a new drug from the laboratory to the pharmacy, according to estimates from the Tufts Center for the Study of Drug Development.
Any technology that meaningfully shortens even part of that process attracts attention quickly, and that's exactly what's happening with a new AI approach from Amazon Web Services.
AWS has deployed a system built around GraphRAG, a technique that combines knowledge graphs with retrieval-augmented generation. Early pharmaceutical deployments have reported reductions of up to 87% in specific research workflows.
While that doesn't mean drug development itself becomes 87% faster, it represents a significant improvement in parts of the research process that traditionally consume weeks or months.
Why Graphs Change the Game
Standard retrieval-augmented generation, the method most enterprise AI tools rely on, pulls relevant text snippets from a database to help a language model answer questions more accurately.
It works well for straightforward lookups but tends to struggle when the real answer depends on complex relationships between entities: how a specific protein interacts with multiple drug compounds, or how a genetic mutation connects to disease pathways across dozens of studies.
GraphRAG addresses that limitation by structuring information as a network of connected entities rather than a flat collection of documents. Instead of retrieving isolated facts, the model can follow relationships across interconnected data, much like a researcher tracing citations through dozens of scientific papers, but at machine speed and across vastly larger datasets.
"The value isn't just speed, it's the ability to surface connections a human researcher might never think to search for," is the kind of assessment researchers have increasingly made about graph-based AI systems, reflecting a broader consensus that structured retrieval methods outperform simple text search for scientific discovery.
A Pattern, Not a One-Off
This isn't happening in isolation. Pharmaceutical companies including AstraZeneca, Pfizer and Moderna have all invested heavily in AI-driven discovery platforms over the past several years, while cloud providers are racing to provide the infrastructure behind them.
Google Cloud and Microsoft Azure have introduced similar graph-based capabilities for life sciences customers, making AWS's move part of a broader industry trend rather than a standalone breakthrough.
What makes the reported 87% improvement notable is its specificity. AI vendors have long promised faster drug discovery, but measurable reductions in defined research workflows give pharmaceutical companies something concrete to evaluate and replicate.
The Miami Angle
Miami's biotech footprint remains smaller than Boston's or San Diego's, but it continues to grow. The University of Miami's Miller School of Medicine, the Wertheim UF Scripps Institute in nearby Jupiter, and an expanding cluster of health-tech startups attracted by Florida's growing life sciences sector have all added momentum.
Organisations such as Sylvester Comprehensive Cancer Center, along with a rising number of Miami-based digital health startups, are already exploring AI for clinical research and diagnostics.
Cloud-based AI infrastructure is especially valuable for emerging biotech hubs like Miami because it lowers the barrier to advanced research. Rather than investing in expensive supercomputing infrastructure, a startup can access sophisticated AI capabilities through cloud services and focused integration work.
That dynamic has already transformed how many Miami startups approach enterprise software, and life sciences could be next. If GraphRAG-style capabilities become a standard AWS offering rather than bespoke enterprise deployments, smaller research teams and university laboratories across South Florida could gain access to discovery tools that were once reserved for major pharmaceutical companies with multi-billion-dollar R&D budgets.
What This Means for Miami
For Miami's health-tech and biotech founders, this points toward a future where cloud infrastructure becomes as important as laboratory equipment during the early stages of research. Companies that can leverage advanced AI platforms without making enormous capital investments may be able to compete more effectively with larger, established players.
Investors watching South Florida's life sciences sector should also take note. Technologies that reduce research costs and accelerate early discovery could make Miami-based biotech startups more attractive investment opportunities by lowering the capital required to reach proof of concept.
Universities such as the University of Miami and Florida International University, both expanding AI and biomedical research, are also likely to deepen partnerships with cloud providers as they compete for research grants, industry collaborations and commercialisation opportunities. As AI-powered research platforms become more accessible, Miami's growing life sciences ecosystem will be better positioned to participate in the next generation of computational drug discovery.